Contents

Volume 93 Issue 12 | JNNP December 2022

Editorial commentary
1237 Validation of the 2021 EAN/PNS diagnostic criteria for chronic inflammatory demyelinating polyneuropathy
S Kawashima, T Suichi

Neuromuscular
1239 Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy

1247 Application of the 2021 EAN/PNS criteria for chronic inflammatory demyelinating polyneuropathy
Y A Kajihara, S Afzal, L K Loo, HS Goede

1253 Adults with spinal muscular atrophy: a large-scale natural history study shows gender effect on disease

Neurogenetics
1269 Clinical and genetic analysis of familial neuromyelitis optica spectrum disorder in Chinese: associated with ubiquitin-specific peptidase USP18 gene variants
Y Cheng, L Zhou, X Zhang, Z Shi, X Sun, Y Wang, R Li, Y Long, H Zhou, C Quan, A G Kermode, Q Yu, W Qiu

1276 A systematic review of adenovirus-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment
R H Horton, D Saade, T Markati, E Harniss, C G Bonnemann, F Muntoni, L Servais

1289 Clinical features of NOTCH2NL-related neuronal intranuclear inclusion disease
Y Tian, L Zhou, J Cao, B Jiao, S Zhang, Q Xiao, J Xue, Y Wang, H Hang, Y Liu, G Ji, C Mao, C Liu, L Dong, L Zhang, S Zhang, Y Ji, G Zhao, Y Luo, Q Son, Y Zhou, F Yi, X Chen, C Zhou, N Xie, M Luo, L Yao, Y Hu, M Zhang, Q Zeng, L Fang, H-Y Long, Y Xie, L Meng, S Chen, J Du, Q Xu, L Feng, Q Huang, X Hou, J Wang, B Xie, L Zhou, L Long, J Gao, J Wang, X Yan, H Jiang, H Xu, R Duan, B Tang, L Shen

Epilepsy
1299 Efficacy of pulse intravenous methylprednisolone in epileptic encephalopathy: a randomised controlled trial

Neurodegeneration
1262 Neurodegenerative disease risk among former international rugby union players
E R Russell, D F Mackay, D Lyall, K Stewart, J A MacLean, J Robson, J P Pell, W Stewart

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been chosen in conjunction with the BMJ Patient Forum to be of particular interest to patients and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme. See http://authors.bmj.com/open-access/

The article is part of the Impact Commentaries series.
### Contents

**Volume 93 | Issue 12 | JNNP December 2022**

#### Multiple sclerosis

**1306** Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis  

**1317** Rebound of clinical disease activity after fingolimod discontinuation? A nationwide cohort study of patients in Denmark  

**1322** Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry  

**1330** Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis  

#### Movement disorders

**1338** Can brain signals and anatomy refine contact choice for deep brain stimulation in Parkinson’s disease?  
S Xu, W L Lee, T Perera, N C Sinclair, K J Bulluss, H J McDermott, W Thevathasan

#### Neuro-inflammation

**1343** Brain neuronal and glial damage during acute COVID-19 infection in absence of clinical neurological manifestations  
D Plantone, S Locci, I Bergeonti, C Mary, R Cortese, M Mecchi, C Cavallaro, M d’Alessandro, E Bargagli, N De Stefano

#### Electronic page

**e3** The British Neuropsychiatry annual meeting abstracts